Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SCA-136 · 4 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| SCA-136 (200 mg) | DRUG | - |
| SCA-136 (400 mg) | DRUG | - |
| olanzapine (15 mg) | DRUG | - |
| placebo | DRUG | - |
| SCA-136 | DRUG | - |
Inclusion Criteria: * Clinical diagnosis of schizophrenia * Ability to remain hospitalized for at least first 4 weeks of study * Needs hospitalization due to worsening of schizophrenia Exclusion Criteria: * Type 1 or 2 diabetes * Previous use of clozapine * Serious medical illness other than schi...
SCA-136 is an investigational small molecule being developed for the treatment of schizophrenia. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities. The drug has been studied in patients with acute exacerbations of schizophrenia, as well as in healthy volunteers for safety and tolerability assessments.
SCA-136 is being developed by Pfizer, Inc. (NYSE: PFE). The company has conducted clinical trials evaluating the drug in patients with schizophrenia and in healthy volunteers. As of the latest data, SCA-136 is in Phase 2 development and remains an investigational compound.
SCA-136 is in Phase 2 clinical development for schizophrenia. It is an investigational drug and has not received regulatory approval. The clinical program includes one Phase 2 study and three Phase 1 studies, all of which have been completed. No active trials are currently listed for this compound.
SCA-136 has been studied in four completed clinical trials. The Phase 2 trial (NCT00265551) evaluated the drug in 300 patients with acute exacerbations of schizophrenia. Three Phase 1 trials (NCT00447941, NCT00458107, NCT00505973) assessed safety, pharmacokinetics, and tolerability in healthy volunteers, including Japanese and non-Japanese subjects.
SCA-136 is a unique investigational compound developed by Pfizer. No alternative names have been reported for this drug. It is a small molecule being studied specifically for schizophrenia and is not known to be identical to any other marketed or investigational medication.